However, combining anti-CD25 treatment with CD1d blockade, thereby inhibiting the activation of type II NKT cells, led to tumor rejection in Jα18 KO mice, indicating that both Treg and type II NKT cells are suppressing tumor immunity in Jα18 KO mice. This evidence concerns the gene CD1D and neoplasm.